Variant "SIRT1:c.-1138T>C"
Search result: 1 record
Variant information
Gene:
Variant:
SIRT1:c.-1138T>C 
Genomic location:
chr10:69643342(hg19) 
HGVS:
SO Term RefSeq
protein_coding NM_012238.4:c.-1138T>C
protein_coding NM_001142498.1:c.-7914T>C
DNAJC12-SIRT1:n.69643342T>C
dbSNP ID:
GWAS trait:
no data 
Modifier statisitcs
Record:
Disorder:
Reference:
Effect type:
Expressivity(1)  
Modifier effect:
Altered severity(1)  
Detail:
  • Target disease:
    Effect type:
    Expressivity 
    Modifier effect:
    Altered severity 
    Evidence:
    PC= 0.012, OR=2.04, 95% CI: 1.32-3.14 
    Effect:
    SIRT1 rs3758391 functionally influences SLE severity and rs3758391 T allele being a risk factor for nephritis and a higher SLEDAI
    Reference:
    Title:
    SIRT1 promoter polymorphisms as clinical modifiers on systemic lupus erythematosus.
    Species studied:
    Human
    Abstract:
    Silent mating type Information Regulator 2 homolog 1 (SIRT1) is a deacetylase protein that participates in several physiological processes with importance in transcriptional silencing, apoptosis, immune system regulation and inflammation. Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease in which upregulated expression of SIRT1 on CD4+ T lymphocytes of active patients has been reported. Also, global hypoacetylation of histones H3 and H4, with H3 hypoacetylation was correlated with a higher disease activity index. SIRT1 promoter rs12778366 and rs3758391 may account for differential expression of this molecule and the role of these variants was investigated in SLE susceptibility and morbidity. Genomic DNA was extracted from peripheral blood of 367 SLE patients and 290 healthy controls of a Southern Brazilian population. SIRT1 rs12778366 and rs3758391 were amplified through PCR and genotyped through sequencing. No statistically significant differences were observed between patients and controls for allelic, genotypic or haplotypic frequencies. Nevertheless, SIRT1 rs3758391 was not in Hardy-Weinberg equilibrium, presenting a paucity of CT heterozygous both in patients and controls. SLE patients with TT and CT genotypes displayed a higher chance of developing lupus nephritis (Pc = 0.012, OR = 2.04 95 % CI 1.32-3.14) and presented a higher disease activity index (Mean rank 170.95 vs 137.26, Pc = 0.006) when compared with CC homozygous patients. Our results suggest that SIRT1 rs3758391 modifies SLE morbidity, with rs3758391 T allele being a risk factor for nephritis and a higher SLEDAI. Nevertheless, it remains to be elucidated how SIRT1 rs3758391 functionally influences SLE severity.